Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia

Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic... Haematologia , Vol. 32, No. 2, pp. 169– 173 (2002) Ó VSP 2002. Also available online - www.vsppub.com Case report Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia KONSTANTINOS ANARGYROU, GEORGE VAIOPOULOS, EVANGELOS TERPOS, MARIA TSIRONI, KONSTANTINOS KONSTANTOPOULOS, MICHAEL SAMARKOS and JOHN MELETIS ¤ First Department of Internal Medicine, University of Athens School of Medicine, Laiko General Hospital, Athens, Greece Abstract —We present the case of a 71 year-old man with secondary acute myeloblastic leukemia, who was successfully treated with low dose melphalan plus Epo plus G-CSF. We treated the patient with 2 mg of melphalan once a day orally, G-CSF 5 mg/kg 3 times a week and Epo 10.000 ui subcutaneously 3 times a week until the maximum response was obtained. Complete remission was achieved after 16 weeks of continuous treatment. Treatment-related toxicity was not signiŽ cant. We recommend the use of low dose melphalan in elderly patients with high risk MDS as a treatment option. Key words : Myelodysplastic syndrome; MDS; refractory anemia; blasts; RAEB; RAEB-t; secondary leukemia; AML-MDS; melphalan treatment. INTRODUCTION Myelodysplastic syndromes (MDSs) are a heterogeneous group of bone marrow clonal disorders http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Haematologia Brill

Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia

Loading next page...
 
/lp/brill/low-dose-melphalan-is-a-treatment-option-in-elderly-patients-with-high-5ThbaXMHAC

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Brill
Copyright
© 2002 Koninklijke Brill NV, Leiden, The Netherlands
ISSN
0017-6559
eISSN
1568-5594
DOI
10.1163/156855902320388023
Publisher site
See Article on Publisher Site

Abstract

Haematologia , Vol. 32, No. 2, pp. 169– 173 (2002) Ó VSP 2002. Also available online - www.vsppub.com Case report Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia KONSTANTINOS ANARGYROU, GEORGE VAIOPOULOS, EVANGELOS TERPOS, MARIA TSIRONI, KONSTANTINOS KONSTANTOPOULOS, MICHAEL SAMARKOS and JOHN MELETIS ¤ First Department of Internal Medicine, University of Athens School of Medicine, Laiko General Hospital, Athens, Greece Abstract —We present the case of a 71 year-old man with secondary acute myeloblastic leukemia, who was successfully treated with low dose melphalan plus Epo plus G-CSF. We treated the patient with 2 mg of melphalan once a day orally, G-CSF 5 mg/kg 3 times a week and Epo 10.000 ui subcutaneously 3 times a week until the maximum response was obtained. Complete remission was achieved after 16 weeks of continuous treatment. Treatment-related toxicity was not signiŽ cant. We recommend the use of low dose melphalan in elderly patients with high risk MDS as a treatment option. Key words : Myelodysplastic syndrome; MDS; refractory anemia; blasts; RAEB; RAEB-t; secondary leukemia; AML-MDS; melphalan treatment. INTRODUCTION Myelodysplastic syndromes (MDSs) are a heterogeneous group of bone marrow clonal disorders

Journal

HaematologiaBrill

Published: Jan 1, 2002

Keywords: RAEB-T; BLASTS; REFRACTORY ANEMIA; SECONDARY LEUKEMIA; MELPHALAN TREATMENT; MYELODYSPLASTIC SYNDROME; RAEB; MDS; AML-MDS

There are no references for this article.